raisetheimage, BP is in the best position to turn Vascepa into a Mega-Blockbuster drug. If not in the US, then certainly in Europe. Who do you think would have a better chance...a BP with decades of experience with seasoned sales reps who know the ropes? Or JT's creating yet another expensive sales force? The sooner BP owns this the more likely it will be that they can lock up feed-stock to prevent generics from buying in bulk. Vascepa is a great drug which JT has managed to lay to waste in the US...and you want him to figure out Europe? JT sounds like a child with a childs mentality when he talks. Get him to either sell the company for a reasonable price...or go away. Certainly the BOD could hire someone much more appealing to be the mouthpiece for AMRN as well as to find a buyer for the company.